PATENT CLAIM ANALYSIS

Application Number: 15768025
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "210210"]

Abstract:
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Claim (Index 43):
Compounds for the use according to any one of the preceding claims, wherein the diseases related to or caused by increased iron levels or tissue iron overload are selected from inflammation triggered by excess iron.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.25532
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15769148', '14310254', '15517528', '14007533', '15185186']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7903643544653846
- 35 USC 102 Novelty (BERT): 0.5499475666220468
- Combined Prediction Score: 0.7663226756810507
- Mean Citation Score: 298.633386
- Max Citation Score: 422.5474
- Similarity Product: 290.5536483810067

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test